NeuroOne Medical Tech 주식 (NASDAQ: NMTC)

에 대한 최신 뉴스 NeuroOne Medical Tech (NASDAQ:NMTC) 주식

NeuroOne Medical Tech

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NMTC

SGMO

금요일(4일) 아침 미국 지수 선물이 하락세를 보이는 가운데, 오늘 투자자의 관심을 끌 수 있는 주식은 다음과 같다. 금요일 주목해야 할 주식: 아메리칸 셰어드, 게스, 뉴로원 메디컬, 시뮬레이션스 및 상가모 테라퓨틱스

금요일 주목해야 할 주식: 아메리칸 셰어드, 게스, 뉴로원 메디컬, 시뮬레이션스 및 상가모 테라퓨틱스

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Technologies Corp

Marin Software Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares are trading lower by 50.8% to 63 cents during Thursday&#8217;s session after the company <a href="https://www.benzinga.com/pressreleases/25/04/b44732652/marin-software-announces-plan-of-dissolution">announced plans for dissolution</a>, which its board of directors has approved.
What Else: Marin says this decision follows a comprehensive review of strategic alternatives by the Board of Directors, who concluded that an orderly wind-down would best serve stockholders.
If stockholder approval occurs, the company will shut down operations, delist from Nasdaq, settle outstanding obligations, seek opportunities to sell off assets and distribute any remaining proceeds to shareholders.
CEO and founder Christopher Lien expressed gratitude to stakeholders for their longstanding support. Marin plans to hold a special shareholder meeting in the second quarter of 2025 and will soon file related materials with the SEC.
Read Also: <a href="https://www.benzinga.com/25/04/44740737/inflation-cools-but-too-soon-to-blow-the-all-clear-economist-says">Inflation Cools, But &#8216;Too Soon To Blow The All Clear,&#8217; Economist Says</a>
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MRIN has a 52-week high of $5.45 and a 52-week low of $0.55.

MRIN

Why Marin Software (MRIN) Stock Is Down 50%

SolarEdge Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) shares are trading lower by 19.4% to $11.56 during Thursday&#8217;s session. The <a href="https://investors.solaredge.com/static-files/e85e20f5-7839-4e31-a97c-7046dd17a39e">company earlier announced</a> that Marcel Gani has resigned from its Board of Directors, effective April 8.
Additionally, board member Dirk Hoke has informed the company that he will not seek re-election at the 2025 Annual Meeting of Shareholders and will step down upon the election of new directors.
What Else: The company clarified that neither departure was due to disagreements regarding operations or governance. In response, the Board adjusted its size—reducing it from ten to nine members effective immediately, with a further reduction to eight members to occur following Hoke's exit.
SolarEdge Technologies&#8217; stock is also likely falling Thursday due to the broader market downturn triggered by renewed economic uncertainty, <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44744139/wall-street-tumbles-dollar-crashes-gold-hits-record-highs-as-inflation-cools-more-than-predicted-whats-driving-markets-thursday">despite positive inflation data</a>. Investors are digesting <a href="https://www.benzinga.com/25/04/44728428/sp-500-records-biggest-surge-since-2008-as-trump-pauses-tariffs-investor-fear-eases-but-fear-greed-index-remains-in-extreme-fear-zone">tariff pauses</a> and lingering economic risks.
Read Also: <a href="https://www.benzinga.com/25/04/44740737/inflation-cools-but-too-soon-to-blow-the-all-clear-economist-says">Inflation Cools, But &#8216;Too Soon To Blow The All Clear,&#8217; Economist Says</a>
<h2 class="wp-block-heading">How To Buy SEDG Stock</h2>
By now you're likely curious about how to participate in the market for SolarEdge Technologies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SEDG has a 52-week high of $72.10 and a 52-week low of $10.24.

SEDG

SolarEdge Technologies (SEDG) Stock Is Down 19%: What's Going On?

Macquarie analyst Steve Koenig upgrades Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) from Neutral to Outperform and lowers the price target from $317 to $270.

Upgrades

Price Target

Analyst Ratings

TEAM

Macquarie Upgrades Atlassian to Outperform, Lowers Price Target to $270

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $18 price target.

GOVX

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $18 Price Target

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has just triggered <a href="https://www.benzinga.com/topic/death-cross">a technical Death Cross</a> — and it's not the only signal weighing on investor sentiment.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="628" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10130413/Screenshot-2025-04-10-at-10.34.03-PM.png" alt="" class="wp-image-866448" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10130413/Screenshot-2025-04-10-at-10.34.03-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10130413/Screenshot-2025-04-10-at-10.34.03-PM-300x236.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Technical Warning signs Pile Up For TSM Stock</h2>
Technically, things look bleak. With shares down 25% year to date and 11% in the past month, TSM stock has sunk below its eight, 20, and 50-day simple moving averages—a textbook sign of a strongly bearish trend. Even the 200-day simple moving average, at $184.40, sits far above TSM stock, at $150.69, offering little comfort.
The Moving Average Convergence Divergence (MACD) stands at a negative 9.07, flashing more red, while the Relative Strength Index (RSI) at 37.85 signals it&#8217;s approaching oversold territory.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44724362/chip-stocks-surge-as-trump-pauses-tariffs-for-us-allies-targets-china-with-125-duties">Chip Stocks Surge As Trump Pauses Tariffs For US Allies, Targets China With 125% Duties</a>
<h2 class="wp-block-heading">Trump Turns Up The Heat On Chipmakers</h2>
But here&#8217;s the kicker: just as TSM tries to steady the ship, President Donald Trump adds political torque. The president claimed he threatened the chip giant with a 100% tax if it didn't make chips in the U.S., <a href="https://www.businessinsider.com/trump-threatened-tsmc-100-percent-tax-make-chips-in-us-2025-4">reported</a> Business Insider. "These chip companies are loaded," he said, slamming the CHIPS Act and boasting he didn't need to write checks to make things happen &#8211; just dangle tariffs.
<h2 class="wp-block-heading">A $100 billion Answer- But Is It Enough?</h2>
TSMC, to its credit, has committed over $100 billion to build five U.S. factories, on top of the $65 billion already pledged. Still, the market isn't exactly applauding. Investors are stuck between a death cross and a Trump tax threat &#8211; and both sides sting.
Investors seeking safer exposure to the chip sector may consider diversified ETFs such as the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>), or VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>), which reduce reliance on any single, politically sensitive stock.
With mounting technical pressure and renewed political scrutiny, TSMC shares face a challenging path ahead. Investors may prefer to wait for signs of technical stability and greater policy clarity before reengaging.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44725578/technology-stocks-outperform-after-trumps-tariff-pause-microchip-technology-amd-lead-sector-higher">Technology Stocks Outperform After Trump&#8217;s Tariff Pause: Microchip Technology, AMD Lead Sector Higher</a></li>
</ul>
Photo: Shutterstock

Technicals

Tech

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TSMC Triggers Death Cross As Trump Tariff Threats Add To Investor Concerns

WIIM

BRBR

CASY

Coca-Cola European Partners plc Ordinary Shares

CCEP

COKE

FIZZ

PSMT

SISI

SMPL

Shares of several consumer staples stocks are trading higher. The sector may be moving up as investors gravitate towards more defensive assets following market-wide volatility and uncertainty.

<a href="https://cwa-union.org/news/tentative-agreement-att-southwest" title="https://cwa-union.org/news/tentative-agreement-att-southwest">https://cwa-union.org/news/tentative-agreement-att-southwest</a>

CWA Says 4-Year Agreement At AT&T Southwest Includes 14.5% Pay Hike Over Life Of Contract, Additional Healthcare Options

Cryptocurrency analyst Benjamin Cowen is urging caution as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continues to trade around key levels, warning that the market's recent bounce may not <a href="https://www.benzinga.com/partner/cryptocurrency/25/04/44665090/a-strategy-that-limits-btcs-inherent-volatility-risk-a-deep-dive-into-calamos-etfs">mark the end of volatility.</a>
What Happened: Speaking in his <a href="https://www.youtube.com/watch?v=sKK9yzBhTmI">podcast</a> on Wednesday, Cowen said President Trump&#8217;s 90-day pause on tariff hikes is widely seen as a bullish macro signal, but it may only be a temporary relief. 
"The tariffs on China actually increased, and considering how much business we do with them, that's not something to brush off," he explained.
He emphasized that markets often experience sharp rebounds after a 20% drop, as seen with the S&amp;P 500 recently, but historical analogs suggest those rallies don't always last. "This kind of volatility doesn't just vanish," Cowen noted.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44735975/bitcoin-back-above-80000-what-does-technical-analysis-say">Bitcoin Back Above $80,000: What Does Technical Analysis Say?</a>
Why It Matters: For Bitcoin, Cowen sees $69,000 as critical support and still preserve the overall bullish structure he said but cautioned that losing that level could flip his outlook more bearish.
He added that despite short-term choppiness, Bitcoin continues to hold above its previous 2024 highs — a sign of strength. Still, the macro backdrop remains uncertain and could weigh on risk assets, especially if China-related tensions escalate.
What's Next: Cowen outlined two potential scenarios:
<ul>
<li>If the market mimics prior non-recessionary corrections, Bitcoin could continue climbing.</li>
<li>If it follows the 1998-style playbook, BTC might form an intermediate top in mid-to-late April, then retest recent lows before pushing back to previous highs by July.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44733485/bitcoin-breaks-80000-but-artificial-rally-could-end-in-a-bear-market-in-september-analyst-warns">Bitcoin Breaks $80,000, But &#8216;Artificial Rally&#8217; Could End In A Bear Market In September, Analyst Warns</a></li>
</ul>
Image: Shutterstock

$BTC

Bitcoin Back Below $80,000 After Relief Rally: What's Next?

Communication Workers Of American Says Last Night CWA AT&T Southwest Bargaining Team Announced They Reached Tentative Agreement With AT&T

As gold prices spike to 18-month highs, investors are turning to <a href="https://www.benzinga.com/etfs">ETFs to achieve exposure to the metal </a>without the hassle of direct ownership.
Geopolitical tensions have heightened amid the tariff game and markets continue to swing wildly. Against this backdrop, gold has resumed its role as a safe haven — and a few ETFs stand out for performance and value.
Also Read: <a href="https://www.benzinga.com/news/global/25/04/44742696/hang-seng-skids-into-bear-zone-as-us-china-tariff-war-rattles-global-etfs">Hang Seng Skids Into Bear Zone As US-China Tariff War Rattles Global ETFs</a>
Global physically backed gold ETFs experienced robust inflows of $8.6 billion in March alone, as per recent <a href="https://www.gold.org/goldhub/data/global-gold-backed-etf-holdings-and-flows">figures </a>from the World Gold Council, taking total first quarter inflows to $21 billion — the second-highest quarterly total in dollar terms ever. The only other time inflows were greater? The second quarter of 2020, during the peak of the COVID-19 pandemic-related pandemonium.
North America dominated the surge, with $6.5 billion of March flows and $12.9 billion for the quarter, or approximately 76% of total. This dramatic rise mirrors a larger investor shift to gold, particularly as volatility shakes both equity and bond markets.
Here are three gold ETFs investors might want to have on their watchlist:
Franklin Responsibly Sourced Gold ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FGDL#NYSE">FGDL</a>)
Year-to-date (YTD) Return: 20.83%
Expense Ratio: 0.15%
FGDL is the top performer when it comes to returns this year so far. What makes it stand out is its emphasis on responsibly sourced gold, appealing to investors who care about ESG factors as much as returns.
SPDR Gold MiniShares Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLDM#NYSE">GLDM</a>)
YTD Return: 20.89%
Expense Ratio: 0.10%
A smaller and cheaper sibling to the heavy-hitting SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), GLDM provides low-cost investors with direct ownership of physical gold without giving up liquidity.
iShares Gold Trust Micro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAUM#NYSE">IAUM</a>)
YTD Return: 20.91%
Expense Ratio: 0.09%
Tailored for retail investors, this ETF provides good performance at ultra-low costs (the lowest in the space today) — an effective play on the gold theme.
Also Read: <a href="https://www.benzinga.com/government/regulations/25/04/44730455/bearish-sentiment-hits-7-week-high-mimicking-35-year-old-record-which-marked-the-bottom-of-the-october-1990-bear-market">Bearish Sentiment Hits 7-Week High, Mimicking 35-Year Old Record Which Marked The Bottom Of The October 1990 Bear Market</a>
<h1 class="wp-block-heading">Why the Gold Rush Now?</h1>
This increased demand for gold is occurring in the face of increasing uncertainty in global markets, fueled primarily by the latest news in U.S. trade policy.
Earlier this week, President Donald Trump <a href="https://www.benzinga.com/topic/tariffs">imposed tariffs on 60 nations</a>, causing a global risk-off sentiment. Although he subsequently introduced a <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty">90-day delay of duties</a> for the majority of nations — led by the European Union — the action was not extended to China, which was slapped with a 125% tariff increase. Beijing promptly fired back with an 84% tariff, fueling concerns of an ongoing U.S.-China trade war.
The see-saw tariff policy has had investors grasping for answers. Gold <a href="https://www.bnnbloomberg.ca/markets/gold/2025/04/10/gold-climbs-after-levy-chaos-drives-biggest-gain-in-18-months/#:~:text=Gold%20rose%20again%20after%20posting,last%20week's%20all%2Dtime%20high.">jumped </a>3.3% on Wednesday, then another 1.6% on Thursday, to within $50 of its record high. The metal is up almost 19% year-to-date.
Markets rallied temporarily on the news of the tariff reprieve. The S&amp;P 500 rose almost 10% — its best day since the financial crisis — after hanging by a thread from a bear market. But the rally has not watered down gold&#8217;s appeal, particularly as investors prepare for more uncertainty and possible central bank intervention.
A weakening dollar and anticipation of additional Federal Reserve easing are fueling the rally. Spot gold increased 1.1% to $3,117.15 an ounce in London on Thursday, as the Bloomberg Dollar Spot Index fell for a second day.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/44698920/as-trump-tariffs-spark-panic-investors-rush-into-these-5-recession-proof-etfs">As Trump Tariffs Spark Panic, Investors Rush Into These 5 &#8216;Recession-Proof&#8217; ETFs</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Commodities

ETFs

FGDL

GLDM

IAUM

Gold Fever Grips Wall Street: These ETFs Are Striking It Rich

Wells Fargo analyst Elyse Greenspan maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Overweight and lowers the price target from $277 to $271.

Wells Fargo Maintains Overweight on RenaissanceRe Holdings, Lowers Price Target to $271

Wells Fargo analyst Elyse Greenspan maintains Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) with a Equal-Weight and lowers the price target from $370 to $362.

Wells Fargo Maintains Equal-Weight on Everest Group, Lowers Price Target to $362

Wall Street trimmed steep losses in afternoon trading Thursday, following remarks from President Donald Trump, who expressed some optimism about reaching trade <a href="https://www.benzinga.com/topic/china">agreements, particularly with China</a>. 
"Would love to be able to work a deal with China," Trump told reporters at the White House. "I think we will end up working out something good for both nations.&#8221;
Trump raised the tariff on imports from China, America's largest trading partner, to 125% on Wednesday. 
&#8220;I think it&#8217;s going to work out,&#8221; Trump added.
Markets reacted swiftly. By 2:50 p.m. ET: 
<ul>
<li>The S&amp;P 500 — tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — was down 3.2%</li>
<li>The Nasdaq 100 trimmed its decline to over 3.8%</li>
<li>The Russell 2000 was off 3.68%. </li>
<li>The Dow Jones Industrial Average also recovered, paring earlier losses from over 4% midday to 2.34%.</li>
</ul>
At midday, the S&amp;P 500 was down 4.8%, the Nasdaq 100 had plunged 5.4%, and the Russell 2000 had dropped 5.3%, wiping out nearly half of Wednesday's historic gains.
<h3 class="wp-block-heading">10% Baseline</h3>
Trump also attacked past trade policies, blaming NAFTA for the loss of nearly 90,000 factories and six million jobs—losses he claimed could have been avoided if tariffs had been in place earlier.
"We're going to bring them all back," Trump said.
Trump highlighted that the European Union initially planned to retaliate against U.S. tariffs but held back after seeing the U.S.&#8217;s aggressive stance against China. &#8220;They were very smart,&#8221; he said.
He also mentioned flexibility in tariff negotiations, suggesting that each country or company might be treated differently depending on the circumstances. 
&#8220;It&#8217;s possible that I would consider flexibility for countries and companies,&#8221; Trump said. &#8220;10% tariff is a baseline. But deals are all different, every country is different.&#8221;
Trump laid out potential uses for the money raised through tariffs, including paying down national debt, reducing the budget and creating border walls.
<h3 class="wp-block-heading">Market Reactions: Gold Eyes Record Close</h3>
At last check Thursday, <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a> data showed:
<ul>
<li>Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) was down 3.6% </li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) down 7%</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) down 3.73%</li>
<li>Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) down 6%, and </li>
<li>Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) down 3.77%.</li>
</ul>
Yields on 30-year Treasury notes were still 8 basis points higher on the day to 4.82%, yet slightly trimming earlier spike during the session.
Gold, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), traded 2.5% higher to $3,160 per ounce, on track to close at fresh record highs. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell 3.9% to below $79,500, erasing nearly all Wednesday&#8217;s gains occurred following the 90-day tariff pause announcement.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns">China&#8217;s Growth Outlook Dims As Trump&#8217;s 125% Tariffs Put Millions Of Jobs At Risk, Goldman Warns</a></li>
</ul>
Image: Shutterstock

Asia

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Econ #s

Economics

PLTR

TSLA

China Deal Is 'Going To Work Out,' Trump Says As Stocks Bounce From Session Lows

Wells Fargo analyst Elyse Greenspan maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Overweight and raises the price target from $317 to $320.

Wells Fargo Maintains Overweight on Progressive, Raises Price Target to $320

Wells Fargo analyst Elyse Greenspan maintains Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) with a Equal-Weight and raises the price target from $97 to $105.

ROOT

Wells Fargo Maintains Equal-Weight on Root, Raises Price Target to $105

Ratings for AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $492.64, along with a high estimate of $650.00 and a low estimate of $335.00. This current average has increased by 19.26% from the previous average price target of $413.07. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311660_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of AppLovin among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;James Callahan &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $425.00&#x7C;$575.00 &#x7C; 
&#x7C;Matthew Cost &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $350.00&#x7C;$470.00 &#x7C; 
&#x7C;Alec Brondolo &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $386.00&#x7C;$538.00 &#x7C; 
&#x7C;Rob Sanderson &#x7C;Loop Capital &#x7C;Raises &#x7C;Buy &#x7C; $650.00&#x7C;$450.00 &#x7C; 
&#x7C;Jason Bazinet &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $600.00&#x7C;$460.00 &#x7C; 
&#x7C;Martin Yang &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $560.00&#x7C;$480.00 &#x7C; 
&#x7C;Mike Hickey &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $525.00&#x7C;$375.00 &#x7C; 
&#x7C;Cory Carpenter &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $475.00&#x7C;$325.00 &#x7C; 
&#x7C;James Callahan &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $575.00&#x7C;$400.00 &#x7C; 
&#x7C;John Hodulik &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $630.00&#x7C;$440.00 &#x7C; 
&#x7C;Omar Dessouky &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $580.00&#x7C;$375.00 &#x7C; 
&#x7C;Eric Sheridan &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Neutral &#x7C; $335.00&#x7C;$220.00 &#x7C; 
&#x7C;John Hodulik &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $440.00&#x7C;$315.00 &#x7C; 
&#x7C;Alec Brondolo &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $366.00&#x7C;$360.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AppLovin. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AppLovin compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AppLovin's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AppLovin's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AppLovin analyst ratings.</a>
<h2>Delving into AppLovin's Background</h2>
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max, and gaming studios, which develop mobile games. AppLovin announced in February 2025 its plans to divest from the lower-margin gaming studios to focus exclusively on the ad tech platform. AppLovin's primary tool for future growth is Axon 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
<h3>Key Indicators: AppLovin's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3M period, AppLovin showcased positive performance, achieving a revenue growth rate of 44.01% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 43.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AppLovin's ROE stands out, surpassing industry averages. With an impressive ROE of 59.04%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): AppLovin's ROA stands out, surpassing industry averages. With an impressive ROA of 10.58%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: AppLovin's debt-to-equity ratio surpasses industry norms, standing at 3.26. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

14 Analysts Assess AppLovin: What You Need To Know

Rumors

CYBN

Trading Circulation Newsletter Mention Of CYBN

In the preceding three months, 5 analysts have released ratings for Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $24.4, a high estimate of $27.00, and a low estimate of $22.00. Surpassing the previous average price target of $23.20, the current average has increased by 5.17%.
<img src="https://www.benzinga.com/files/images/story/2025/1744311652_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Hamilton Insurance Group among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $22.00&#x7C;$23.00 &#x7C; 
&#x7C;Tommy McJoynt &#x7C;Keefe, Bruyette &amp; Woods &#x7C;Raises &#x7C;Outperform &#x7C; $25.00&#x7C;$23.00 &#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $23.00&#x7C;$21.00 &#x7C; 
&#x7C;Matthew Carletti &#x7C;Citizens Capital Markets&#x7C;Raises &#x7C;Market Outperform&#x7C; $27.00&#x7C;$25.00 &#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $25.00&#x7C;$24.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Hamilton Insurance Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hamilton Insurance Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Hamilton Insurance Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Hamilton Insurance Group's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hamilton Insurance Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Hamilton Insurance Group Better</h2>
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
<h3>Hamilton Insurance Group: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Hamilton Insurance Group displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 15.12%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Hamilton Insurance Group's net margin is impressive, surpassing industry averages. With a net margin of 5.82%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Hamilton Insurance Group's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.46%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Hamilton Insurance Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.43%, the company showcases efficient use of assets and strong financial health.
Debt Management: Hamilton Insurance Group's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Hamilton Insurance Group Through 5 Analysts

13 analysts have expressed a variety of opinions on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $194.0, along with a high estimate of $230.00 and a low estimate of $150.00. Observing a 6.55% increase, the current average has risen from the previous average price target of $182.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311642_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $217.00&#x7C;$200.00 &#x7C; 
&#x7C;Jeffrey Hung &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $183.00&#x7C;$175.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $179.00&#x7C;$145.00 &#x7C; 
&#x7C;Gregory Fraser &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $230.00&#x7C;$220.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $200.00&#x7C;$190.00 &#x7C; 
&#x7C;Charles Duncan &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Neutral &#x7C; $150.00&#x7C;$140.00 &#x7C; 
&#x7C;David Amsellem &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $176.00&#x7C;$163.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $178.00&#x7C;$179.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $209.00&#x7C;$200.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $210.00&#x7C;$205.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $170.00&#x7C;$130.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Jazz Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Unraveling the Financial Story of Jazz Pharmaceuticals</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Jazz Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 7.53% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 4.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.57% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.51.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JAZZ

Where Jazz Pharmaceuticals Stands With Analysts

Wells Fargo analyst Elyse Greenspan maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Equal-Weight and lowers the price target from $79 to $69.

VOYA

Wells Fargo Maintains Equal-Weight on Voya Financial, Lowers Price Target to $69

Press Releases

NeuroOne® Regains Compliance with Nasdaq Listing Requirements

NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern Time

NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Health Care

NeuroOne CEO Joins Today's Marketplace To Discuss The Latest Treatments for Epilepsy

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

Biomerica

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Co-Diagnostics

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

Femasys

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

Iridex

NAYA Biosciences

Neuraxis

NeuroMetrix

enVVeno Medical Corporation - Common Stock

enVVeno Medical

Nexalin Technology

PAVmed

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

Trinity Biotech plc - American Depositary Shares

Trinity Biotech

Beyond Air

Xylo Technologies Ltd. - American Depositary Shares

Xylo Technologies

Alliance Global Partners

Screenshot 2024-05-03 at 5.56.54 PM

Biotech

Interview

General

NeuroOne – The Medical Device Company That Has Created A Product That Could Monitor And Treat At The Same Time

Screenshot 2024-03-27 at 5.33.58 PM

NeuroOnes&#39;s Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders

Screenshot 2024-03-07 at 8.32.36 PM

Movers & Shakers

ATITK

NeuroOne Medical Technologies&#39; (NASDAQ: NMTC) Innovative Brain Monitoring Tech Developing And Commercializing Electrodes To Provide Insights To Help Physicians Treat Neurological Disorders Like Epilepsy

금요일(4일) 아침 미국 지수 선물이 하락세를 보이는 가운데, 오늘 투자자의 관심을 끌 수 있는 주식은 다음과 같다.
<ul>
<li>아메리칸 셰어드 호스피털 서비스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMS#NYSE">AMS</a>): 금요일 개장 전 실적을 발표할 예정이며, 매출 770만 달러 및 주당순이익 1센트가 예상된다. 주가는 목요일 애프터마켓에서 0.3% 상승하여 2.97달러에 거래되었다.</li>
<li>게스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>): 4분기에 긍정적인 실적을 발표하고 알베르토 토니를 CFO로 임명했다. 2026회계연도 매출이 미국 달러로 3.9%~6.2% 증가하고 조정 주당순이익이1.32~1.76달러가 될 것으로 예상한다고 밝혔다. 주가는 목요일 애프터마켓에서 2.4% 하락하여 9.80달러에 거래되었다.</li>
<li>뉴로원 메디컬 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>): 보통주 공개 발행을 발표했다. 주가는 목요일 애프터마켓에서 36.1% 하락하여 0.5499달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인하세요.
<ul>
<li>시뮬레이션스 플러스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>): 2분기에 예상보다 강한 실적을 발표하고 2025회계연도 수익 전망을 긍정적으로 제시했다. 주가는 목요일 애프터마켓에서 2.5% 상승하여 24.41달러에 거래되었다.</li>
<li>상가모 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>): 제약 대기업 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 새로운 계약을 발표하며, 상가모의 독창적인 신경영향 아데노 바이러스(AAV) 캡시드인 STAC-BBB에 대한 전세계 독점 라이센스를 부여받았다. 주가는 목요일 애프터마켓에서 47.7% 급등하여 0.9193달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

NeuroOne Medical Tech

뉴스

에 대한 최신 뉴스 NeuroOne Medical Tech (NASDAQ:NMTC) 주식

금요일, 4월 04, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌